Adebrelimab

Adebrelimab is a drug that is being evaluated for the treatment of solid tumors. Adebrelimab is recombinant humanized IgG4 monoclonal antibody with specificity for PD-L1.

In 2023, adebrelimab was approved for use in China for the treatment of small cell lung cancer.